APOL1 variants associate with increased risk of CKD among African Americans

Journal of the American Society of Nephrology

Volumn 24, Issue 9, 2013, Pages 1484-1491

  Foster, Meredith C ^a,b   Coresh, Josef ^a,c   Fornage, Myriam ^d   Astor, Brad C ^e   Grams, Morgan ^a,b,c   Franceschini, Nora ^f   Boerwinkle, Eric ^d   Parekh, Rulan S ^a,c,g   Kao, W H L ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f IL   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

ADULT; AFRICAN AMERICAN; ALLELE; APOL1 G1 GENE; APOL1 G2 GENE; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FEMALE; GENE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 84884327585     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013010113     Document Type: Article

References (26)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. US Renal Data System: USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277: 1293-1298, 1997
4. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J AmSoc Nephrol 13: 2363-2370, 2002
5. Perneger TV, Whelton PK, Klag MJ: Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 155: 1201-1208, 1995
6. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS; Family Investigation of Nephropathy andDiabetes Research Group:MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008
7. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184, 2008
8. GenoveseG, FriedmanDJ, RossMD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010
9. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N,WasserWG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to theMYH9 gene. HumGenet 128: 345-350, 2010
10. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, SmithMC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J AmSoc Nephrol 22: 2129-2137, 2011
11. Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D'Agati VD, Klotman PE, Gharavi AG: APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22: 1991-1996, 2011
12. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114-120, 2013
13. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR: Populationbased risk assessment of APOL1 on renal disease. J Am Soc Nephrol 22: 2098-2105, 2011
14. Freedman BI, Langefeld CD, Turner J, NúñezM, High KP, Spainhour M, Hicks PJ, BowdenDW, Reeves-Daniel AM,MureaM, RoccoMV, Divers J: Association of APOL1 variants with mild kidney disease in the firstdegree relatives of African American patients with non-diabetic endstage renal disease. Kidney Int 82: 805-811, 2012
15. O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, Köttgen A, Coresh J, Yang Q, Fox CS, KaoWH: TheMYH9/APOL1 region and chronic kidney disease in European-Americans. HumMol Genet 20: 2450-2456, 2011
16. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P,Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N,Dieu M, Kane JP,De Baetselier P, Brasseur R, Pays E: Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422: 83-87, 2003
17. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, Malloy MJ, Kane JP: Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272: 25576-25582, 1997
18. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR: APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22: 2119-2128, 2011
19. de Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early marker for cardiovascular disease. JAmSocNephrol 17: 2100-2105, 2006
20. Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K: The population genetics of chronic kidney disease: Insights from the MYH9-APOL1 locus. Nat Rev Nephrol 7: 313-326, 2011
21. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
22. TheARIC Investigators: TheAtherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 129: 687-702, 1989
23. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J: Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20: 2617-2624, 2009
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
25. Bash LD, Astor BC, Coresh J: Risk of incident ESRD: A comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 55: 31-41, 2010
26. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, SmithMW,O'Brien SJ, Altshuler D, DalyMJ, Reich D: Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74: 979-1000, 2004